EGRIFTA SV™ is a newly FDA approved treatment* for Hard Belly (excess hard abdominal fat) in adult patients living with HIV and lipodystrophy.
EGRIFTA SV™ is not indicated for weight loss management; the impact and safety on cardiovascular health have not been studied; and it is not known whether taking EGRIFTA SV™ helps improve compliance with anti-retroviral medications.
EGRIFTA SV™ is a daily treatment that you inject subcutaneously (under the skin) around your lower abdomen (belly).
People who used EGRIFTA SV™continually for one year saw significant reductions in Hard Belly (excess hard abdominal fat) over this time period.
Hard Belly (excess hard abdominal fat) returned when EGRIFTA SV™ was stopped after 6 months of therapy.